Quintiles Library

Brochure RWLP Expertise in Rare Diseases
Featured Brochure

Developing evidence for medical breakthroughs: Real-world & late phase expertise in rare diseases
With the list of rare diseases across the globe expanding to nearly 7,000 it is critical to make new treatments available for these uncommon conditions. While regulatory incentives and the designation of “orphan” products have stimulated commercial research for rare diseases, their low prevalence, high complexity and predominance in children create significant barriers. Providers and patients are clamoring for treatment access and improved outcomes, but increasingly...
Fact Sheet
Ahora puede reducir, de principio a fin, la carga administrativa que conlleva la investigación clínica. Quintiles Infosario Site Gateway le da acceso, en un práctico espacio de trabajo en línea, a datos centralizados para sus estudios gestionados por Quintiles. Dado que Quintiles utiliza este mismo sistema para la identificación y selección del centro de investigación, usted puede actualizar su perfil directamente en esta plataforma en línea, para asegurarse de que se comuniquen con usted, para ofrecerle las oportunidades de estudio que mejor se ajusten a sus posibilidades. El hecho de usar esta misma información le permite rellenar formularios de información de su centro para acelerar su respectiva...
Read More
Video
Badhri Srinivasan, Senior Vice President and Head, Global Data and Safety Monitoring at Quintiles, discusses how Clinical Data Management (CDM) is making a move from the more traditional activity-based or “data curator” role to a very critical “information based” role.In this short video, Srinivasan discusses with some other senior leaders at Quintiles how it has quickly become an industry requirement that CDM teams must not only maintain data integrity, but also interpret data, identify signals and better predict trial outcomes through a more rigorous medical analysis – which will ultimately transform clinical development and improve our customers’ probability of success. This is the player to use for single videos on Q.com ...
Fact Sheet
With nearly 1% of the world's population affected by rheumatoid arthritis, you need one global partner to support your research from discovery to post-market. Learn about how our clinical resources and global labs have helped us develop or commercialize the top 40 rheumatology drugs of...
Read More
Fact Sheet
Quintiles Infosario Site Gateway enables sites to easily manage time-consuming clinical trial tasks. With our single user-friendly system, sites can take advantage of a wide range of services, transforming clinical development. With Quintiles Infosario Site Gateway, you can empower your sites with an award-winning online workspace that provides secure on-demand access to the right information. The result? Quicker decision-making for more efficient project delivery — and, ultimately, better patient outcomes. And with greater visibility into centralized site performance data, Quintiles can help select the right sites for your...
Read More
Fact Sheet
Learn about how our clinical resources and global central labs have helped us develop or commercialize the top 45 oncology drugs of...
Read More
Media Coverage
John Procter, Senior Director, Value and Access, says the industry must increasingly prove how products can improve patient outcomes, and adapt its offering to...
Read more
Media Coverage
Jeremy Broadis, Vice President, Commercial Solutions looks at how specialist pharma companies can evaluate a number of options when considering the sometimes daunting prospect of launching their product in...
Read more
Fact Sheet
In this edition, we will look specifically at Latin America. Despite cultural and linguistic similarities among the countries in this region, there are notable socioeconomic differences which are reflected in a variety of health systems. Consequently, different countries are also at different stages in HTA implementation as well as expertise. Click the download button above to read the May...
Read more
Fact Sheet
As Inflammatory Bowel Disease (IBD) severity increases in patients entering studies, trial design is becoming more complex – and finding the right patients is a continuing challenge. Higher risk profiles of new biologics are forcing a tighter focus on safety issues, and market attractiveness is driving strong competition. So how can drug developers successfully overcome the myriad challenges you face? As a market leader in conducting IBD studies across the lifecycle and around the globe, Quintiles has the experience and therapeutic and operational expertise to help you take your IBD therapy from lab to...
Read more
Fact Sheet
For one of the most mature markets in the world, Japan continues to offer huge opportunities for growth. It is the largest pharmaceutical market in the Asia Pacific region and second only to North America worldwide. With government healthcare reforms spurring innovation, Japan equals the promise of emerging countries without the risk. Quintiles’ integrated teams, backed by our global standards, processes and technology, provide the expertise you need to confidently develop and market therapies in Japan. Whether you’re looking to enter Japan only or the larger Asia Pacific market, trust Quintiles to help deliver on your globalization...
Read more
White Paper
Rising costs, increased pressures and heightened expectations have fostered an environment of risk and uncertainty in the drug development and delivery market. The question now is – How can the industry transform itself to thrive in this new era of...
Explore here
Fact Sheet
Pharmaceutical companies are crossing borders around the globe, leading many to seek the best markets for expansion. Japan is often at the top of that list. As the second largest pharma market in the world, Japan offers advantages from universal healthcare coverage to extended patent cycles to government support of innovation. Entering the Japanese market, however, requires a clear understanding of the unique regulatory requirements and advantages of conducting clinical development in Japan. Quintiles’ local In-Country Clinical Caretaker (ICCC) team can help you directly conduct clinical trials in Japan as the drug sponsor.  It’s the option that allows you to retain control and minimize...
Read more
Brochure
治験施設のフィージビリティおよびその戦略 -...
Read more
Fact Sheet
The NHS landscape is evolving rapidly as stakeholders seek to make the best use of scarce resources to achieve the best clinical outcomes for their patient populations.While medicines clearly have a vital role to play in achieving these outcomes, it is becoming increasingly clear that even the most robust evidence base from the best-run clinical trials is no longer enough to guarantee the uptake and use of a new medicine.Through strong partnerships, NHS stakeholders and pharmaceutical companies can ensure that patients gain access to and benefit from the most effective medicines and the NHS makes the best use of scarce...
Read more
Brochure
在临床研究的早期阶段,正确启动研究至关重要。然而,高达70%的临床研究研究都会出现研究启动延迟,而几乎一半的临床研究都未能按时完成。临床研究的时间每推迟一天,患者使用新产品的时间就会延迟一天,而且也会面临失去数以百万计预期收益的风险。凭借整体的综合方法,昆泰能够帮助您显著提升研究结果。Quintiles Right...
Read more
Video
Adrian McKemey, Ph. D, Sr. V.P. and John Doyle, Dr.P.H., MPH, Sr.  V.P., Consulting at Quintiles highlight their thoughts on how the competition is shifting from having and hoarding data to connecting it. This is the player to use for single videos on Q.com...
White Paper
This paper shows how research by Quintiles indicates that study indicates that few subjects experiencing one symptom of neurocognitive decline ever visit their physician, suggesting that there is a large available pool of community-based patients who could potentially participate in pAD clinical trials. Subjects are willing to complete online assessments regarding their symptoms, and thus a digitally-based community outreach pre-screening campaign would help identify and screen potentially appropriate trial subjects, and eliminate inappropriate ones. Thus digital outreach can help make a significant reduction in the burden of work at the site by managing the pre-screening in the community and not within the site and then only a much smaller percentage of subjects would be brought,...
Explore here
Podcast
TRANSCRIPTHello, my name is Nobuyuki Shiga, Senior Director and Chief Medical Officer with Quintiles Japan. I'm a practicing physician and have worked on drug development in the pharmaceutical industry for more than ten years.Today I would like to take a couple of minutes to talk about why more and more multinational companies are discovering the potential of the Japanese market. Quintiles Japan is here to serve such companies including those without a presence in Japan as well as Japanese pharmaceutical companies.Japan is the 2nd largest pharmaceutical market in the world. The Japan pharma market is estimated to grow by CAGR 1.7 – 4.7% in 5 years, which is the highest among established markets.Japan is seen by many as an attractive market for 3 key reasons.First, Japan has a stable...
Fact Sheet
Clinical research into new rheumatoid arthritis treatments has led to substantial progress; however, significant unmet needs still remain. See how Quintiles’ combination of therapeutic expertise, innovative processes and operational experience can help you take your RA compound all the way from lab to market. Ready to get...
Read more
Presentation
Download this presentation given by Priscilla Velentgas, Senior Director of Epidemiology, at the 2014 World Vaccine Congress and learn about the role of epidemiology in post-approval vaccines safety...
Explore more